Best GLP-1 for Weight Loss 2026: Complete Comparison of Semaglutide, Tirzepatide & Retatrutide

## Best GLP-1 for Weight Loss in 2026: An Evidence-Based Comparison The GLP-1 receptor agonist market has expanded rapidly. Three medications now dominate the weight loss conversation: semaglutide (the established standard), tirzepatide (the dual agonist contender), and retatrutide (the triple agonist newcomer). Each works through a different mechanism, produces different average results, and comes at a different price point. We analyzed clinical trial data, real-world prescribing patterns, and patient-reported outcomes to produce this comparison. Our goal is straightforward -- help you understand the objective differences so you can have a more productive conversation with your prescriber. ## How Each Medication Works ### Semaglutide (Single GLP-1 Agonist) Semaglutide activates one receptor: GLP-1. This slows gastric emptying, suppresses appetite centrally, and enhances insulin secretion. It has been on the market since 2017 (Ozempic for diabetes) and 2021 (Wegovy for weight management), giving it the longest real-world safety track record of the three. ### Tirzepatide (Dual GIP/GLP-1 Agonist) Tirzepatide targets two receptors: GLP-1 and GIP. The addition of GIP receptor activation appears to amplify the metabolic effects, improving fat oxidation and insulin sensitivity beyond what GLP-1 alone achieves. FDA-approved as Mounjaro (2022) and Zepbound (2023). ### Retatrutide (Triple GLP-1/GIP/Glucagon Agonist) Retatrutide goes one step further with three receptor targets: GLP-1, GIP, and glucagon. The glucagon component is the key differentiator -- it directly stimulates energy expenditure and hepatic fat oxidation. Currently in Phase 3 clinical trials with FDA approval anticipated in late 2026 or 2027. ## Head-to-Head Efficacy Comparison | Metric | Semaglutide 2.4mg | Tirzepatide 15mg | Retatrutide 12mg | |--------|-------------------|------------------|-------------------| | **Avg. Body Weight Loss** | 15-17% | 20.9% | 24.2% | | **Patients Losing 10%+** | ~70% | ~85% | ~93% | | **Patients Losing 20%+** | ~35% | ~57% | ~63% | | **A1C Reduction** | 1.5-2.0% | 2.0-2.5% | 2.0-2.2% | | **Trial Duration** | 68 weeks | 72 weeks | 48 weeks | | **Key Trial** | STEP 1 | SURMOUNT-1 | Phase 2 | | **FDA Approved** | Yes (2021) | Yes (2022) | No (Phase 3) | **Important caveat:** The retatrutide data comes from a Phase 2 trial with 48 weeks of follow-up. Phase 3 data, which typically enrolls larger and more diverse populations, may show different results. Direct comparisons across trials have inherent limitations. ## Cost Comparison: Brand vs. Compounded | Medication | Brand Monthly Cost | Compounded Monthly Cost | Insurance Coverage | |------------|-------------------|------------------------|--------------------| | **Semaglutide** | $900-1,500 (Ozempic/Wegovy) | $150-300 | Moderate | | **Tirzepatide** | $1,000-1,200 (Mounjaro/Zepbound) | $250-400 | Improving | | **Retatrutide** | N/A (not approved) | $300-500 (research) | None | For patients paying out of pocket, the cost difference between brand and compounded versions is substantial. At [Prost](/products), we offer pharmaceutical-grade compounded semaglutide, tirzepatide, and retatrutide at competitive pricing with third-party purity testing for every batch. ## Dosing Schedules Compared ### Semaglutide Titration - Weeks 1-4: 0.25mg/week - Weeks 5-8: 0.5mg/week - Weeks 9-12: 1.0mg/week - Weeks 13-16: 1.7mg/week - Week 17+: 2.4mg/week (maintenance) ### Tirzepatide Titration - Weeks 1-4: 2.5mg/week - Weeks 5-8: 5mg/week - Weeks 9-12: 7.5mg/week - Weeks 13-16: 10mg/week - Weeks 17-20: 12.5mg/week - Week 21+: 15mg/week (maintenance) ### Retatrutide Titration (Phase 2 Protocol) - Weeks 1-4: 1mg/week - Weeks 5-8: 2mg/week - Weeks 9-12: 4mg/week - Weeks 13-16: 8mg/week - Week 17+: 12mg/week (maintenance) All three are subcutaneous weekly injections. Tirzepatide offers the most granular dose steps, which many clinicians prefer for fine-tuning. For detailed dosing guides, see our [semaglutide dosing guide](/guides/semaglutide-dosing-schedule-week-by-week-guide), [tirzepatide dosing guide](/guides/tirzepatide-dosing-schedule-complete-guide), and [retatrutide dosing guide](/guides/retatrutide-dosing-protocol-complete-titration-guide). ## Side Effect Profile Comparison | Side Effect | Semaglutide | Tirzepatide | Retatrutide | |-------------|-------------|-------------|-------------| | **Nausea** | 40-44% | 25-33% | 25-45% | | **Diarrhea** | 30% | 17-23% | 20-35% | | **Vomiting** | 24% | 12-18% | 15-25% | | **Constipation** | 24% | 12-17% | 15-22% | | **Injection Site Reactions** | 3-5% | 3-7% | 5-10% | | **Sulfur Burps** | Rare | 10-15% | Rare | | **Increased Heart Rate** | Modest | Modest | More notable | Side effects are generally dose-dependent and most severe during titration. Most patients find symptoms manageable by week 8-12. For strategies to reduce GI side effects, see our [semaglutide side effects management guide](/guides/semaglutide-side-effects-how-to-manage). ## Who Should Choose Which Medication? ### Choose Semaglutide If: - You want the longest safety track record (5+ years of real-world data) - Budget is a primary concern (most affordable compounded option) - You need 15-20% body weight loss - You prefer the most extensively studied medication - You have cardiovascular risk factors (SUSTAIN-6 and SELECT trial data support CV benefits) ### Choose Tirzepatide If: - You want maximum FDA-approved weight loss potential (20%+ average) - You have type 2 diabetes along with obesity (strongest A1C data) - You plateaued on semaglutide and want to try a dual mechanism - You prefer more titration steps for a gradual increase ### Choose Retatrutide If: - You have significant weight to lose (BMI 40+) and want the highest potential efficacy - You have fatty liver disease (early data suggests strong hepatic fat reduction) - You are comfortable with a newer agent that lacks Phase 3 data - Previous GLP-1 medications produced insufficient results ## Our Verdict **Best overall: Tirzepatide.** It offers the strongest combination of proven efficacy, FDA approval, and manageable side effects. The 20.9% average weight loss from SURMOUNT-1 represents a meaningful improvement over semaglutide. **Best value: Semaglutide.** With the longest track record, broadest insurance coverage, and most affordable compounded pricing, semaglutide remains the most accessible GLP-1 medication. For many patients, 15-17% weight loss is sufficient to achieve metabolic health goals. **Most promising: Retatrutide.** The Phase 2 data showing 24.2% average weight loss is remarkable. The triple agonist mechanism is scientifically compelling, particularly the glucagon-driven increase in energy expenditure. If Phase 3 data confirms the Phase 2 results, retatrutide could become the new standard. All three medications are available through [Prost's online store](/products) as pharmaceutical-grade compounded formulations with certificates of analysis. --- ## References - Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). *NEJM*, 2021. - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). *NEJM*, 2022. - Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial. *NEJM*, 2023. - Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). *NEJM*, 2021. - Nauck MA, et al. GLP-1 Receptor Agonists: Comparative Efficacy Review. *Diabetes Obes Metab*, 2024.